Localized morphea in children.
We are following 60 patients with morphea and/or linear scleroderma at the Hospital for Sick Children, Toronto. Lesions may vary in depth from epidermal changes resembling lichen sclerosis, to superficial and deep dermal changes. The subcutaneous tissue, bone and muscle may be involved. There is no good clinical marker of the disease. Because of the variation in the time to cure, it is difficult to evaluate treatment regimens. We are currently using methotrexate weekly either orally or subcutaneously and monthly pulsed steroids for three months.
Krafchik
B R
BR
Hospital for Sick Children, Department of Dermatology, Toronto, Ontario, Canada.
D002648:Child; D002675:Child, Preschool; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018459:Lichen Sclerosus et Atrophicus / Q000209:etiology; D008727:Methotrexate / Q000627:therapeutic use; D011379:Prognosis; D012594:Scleroderma, Localized / Q000145:classification / Q000150:complications / Q000188:drug therapy; D012872:Skin Diseases, Vesiculobullous / Q000209:etiology; D013256:Steroids / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D013256:Steroids; D008727:Methotrexate